As required under Regulation 13 (3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, AstraZeneca Pharma India has informed about the Report on Redressal of Investor Complaints for the quarter ended December 31, 2017.
The above information is a part of company’s filings submitted to BSE.